Buckland, MS;
Galloway, JB;
Fhogartaigh, CN;
Meredith, L;
Provine, NM;
Bloor, S;
Ogbe, A;
... Thaventhiran, JED; + view all
(2020)
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.
Nature Communications
, 11
, Article 6385. 10.1038/s41467-020-19761-2.
Preview |
Text
Treatment of COVID-19 with remdesivir in the absence of humoral immunity a case report.pdf - Published Version Download (1MB) | Preview |
Abstract
The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the use of remdesivir in a patient with COVID-19 and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia (XLA). Despite evidence of complement activation and a robust T cell response, the patient developed persistent SARS-CoV-2 pneumonitis, without progressing to multi-organ involvement. This unusual clinical course is consistent with a contribution of antibodies to both viral clearance and progression to severe disease. In the absence of these confounders, we take an experimental medicine approach to examine the in vivo utility of remdesivir. Over two independent courses of treatment, we observe a temporally correlated clinical and virological response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resistance. We therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potential benefit in selected patients.
| Type: | Article |
|---|---|
| Title: | Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41467-020-19761-2 |
| Publisher version: | https://doi.org/10.1038/s41467-020-19761-2 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| Keywords: | Antivirals, Primary immunodeficiency disorders, SARS-CoV-2, Viral infection |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10120120 |
Archive Staff Only
 |
View Item |
